KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Non-Current Liabilities (2016 - 2022)

Inovio Pharmaceuticals (INO) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $126.2 million as the latest value for Q4 2022.

  • Quarterly Total Non-Current Liabilities rose 31.08% to $126.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $126.2 million through Dec 2022, up 31.08% year-over-year, with the annual reading at $126.2 million for FY2022, 31.08% up from the prior year.
  • Total Non-Current Liabilities hit $126.2 million in Q4 2022 for Inovio Pharmaceuticals, up from $124.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $161.7 million in Q2 2022 to a low of $37.0 million in Q3 2018.
  • Historically, Total Non-Current Liabilities has averaged $98.0 million across 5 years, with a median of $102.4 million in 2019.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 211.9% in 2019 and later plummeted 51.53% in 2021.
  • Year by year, Total Non-Current Liabilities stood at $44.1 million in 2018, then surged by 194.29% to $129.7 million in 2019, then tumbled by 39.43% to $78.6 million in 2020, then grew by 22.51% to $96.3 million in 2021, then surged by 31.08% to $126.2 million in 2022.
  • Business Quant data shows Total Non-Current Liabilities for INO at $126.2 million in Q4 2022, $124.6 million in Q3 2022, and $161.7 million in Q2 2022.